Browse by ▼

Terry Chrisomalis

All Posts

  • Can These Stocks Deliver profits?

    By Terry Chrisomalis - May 15, 2013 | Tickers: FDX, LEN, UPS

    When we want to ship a package there are only a few options to choose. One of those options is the United States Postal Service, or USPS; an affordable way for those people who don't need to deliver their packages quickly, and want cheaper standard shipping options. But the USPS has seen some problems in funding from the government, and people prefer to use other shipping service methods. 

    Two more »

  • This Stock Should Get Better in the Long Run

    By Terry Chrisomalis - May 15, 2013 | Tickers: ACAD, MRK, PFE

    ACADIA Pharmaceuticals (NASDAQ: ACAD) has been on a solid run since early last year and it has continued to climb to new highs this year as well. The move that started it all happened in late 2012. On Nov. 27, 2012, ACADIA had announced that their drug, Pimavanserin, had met both primary and secondary endpoints. This trial completed was the pivotal phase 3 trial for Parkinson disease Psychosis. 

    So, as more »

  • SINA Is Worth Your Attention

    By Terry Chrisomalis - May 14, 2013 | Tickers: FB, RENN, SINA

    There is one Chinese company which I believe is worth buying as the market continues to edge to higher levels. The Chinese company that I believe will do well long term is SINA (NASDAQ: SINA). This company still has a long way to go to monetize its assets, so short term the trade is very risky. Although if you are a long term investor then this is a good position more »

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Apple Has Lost Its Way

    By Terry Chrisomalis - May 1, 2013 | Tickers: AAPL, GOOG, NFLX

    Apple (NASDAQ: AAPL)) hit its high of $700 per share in after-hours trading on Sept. 17, 2012. What has happened since then hasn't been favorable for the tech giant at all. So what has gone wrong for Apple, and why has it declined in value so much? It seems that Apple is losing its way of innovating and creating products that fans would love to buy. 

    Let us take more »

  • This Biotech Just Popped, and Might Pop Further

    By Terry Chrisomalis - April 29, 2013 | Tickers: GILD, MRK, VRTX

    Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year. Vertex is a biotech company focused on treating rare diseases with limited treatment options. Vertex has popped big recently on new promising data for patients diagnosed with Cystic fibrosis. 

    Cystic Fibrosis is a rare disease that causes thick mucus to build up in more »

  • Google Keeps Soaring to New Highs

    By Terry Chrisomalis - April 24, 2013 | Tickers: FB, GOOG, MSFT

     Over the years of investing, there are some stocks that continue to edge higher in the midst of certain economic uncertainty. One such company is Google (NASDAQ: GOOG), which has seen its stock go up significantly since its 2008 low of around $300 per share. Over the last five years, the stock has climbed to the point where it is now trading at around $780 per share. Is Google ready more »

  • Should You Place Your Bet on Zynga?

    By Terry Chrisomalis - April 23, 2013 | Tickers: FB, GLUU, ZNGA

    When Zynga (NASDAQ: ZNGA) first came out, it came out with many strong game titles, including Farmville, Cityville, Mafia Wars, and Words with Friends. The company priced its initial public offering at $10 per share -- at that time, the biggest tech IPO offering since Groupon. Zynga included 100 million shares at $10 per share, bringing its valuation to $1 billion. Zynga had a great pop on its IPO, but over more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 19, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask why you should bother investing in this type of biotech stocks? Because these companies treat rare diseases with limited treatment options. 

    In my opinion, these biotech stocks perform better than their peers, and will more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 18, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past when it had partnered with Pfizer, with a drug known as Dimebon. 

    Dimebon had made it up to Phase III, where it had failed more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 16, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drug status. You might ask why invest in these types of biotech stocks? It is quite simple really, these types of companies treat rare diseases with limited treatment options. 

    In my opinion I feel these biotech stocks more »

  • This Retailer Needs to Do More to Stay Relevant

    By Terry Chrisomalis - April 15, 2013 | Tickers: AMZN, BBY, WMT

    Of all the retailers today, it seems that Best Buy (NYSE: BBY) is having the greatest difficulty producing big sales each quarter. The problem with Best Buy is that it is facing stiff competition from online retailers. Best Buy seems to be stuck in the brick and mortar business. This is not good for the company, as online retailers have been stealing market share from physical stores. 

    Best Buy has more »

  • Is RNA Drug Development Coming of Age?

    By Terry Chrisomalis - April 11, 2013 | Tickers: ALNY, ISIS, SRPT

    Of late, it seems that good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On Oct. 2, 2006, Dr. Craig Mello and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

    It has been a long more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 9, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past though, when it had partnered with Pfizer with a drug known as Dimebon. 

    Dimebon had made it up to phase three, where it had more »

  • Is RNA Drug Development Coming Of Age?

    By Terry Chrisomalis - April 8, 2013 | Tickers: ALNY, ISIS, SRPT

    Lately it seems good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On October 2, 2006 Dr. Craig Mello, and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

    It has been a long road for more »

  • Can You Place Your Bet On Zynga?

    By Terry Chrisomalis - April 8, 2013 | Tickers: FB, GLUU, ZNGA

    I would have to say that when Zynga (NASDAQ: ZNGA) first came out, it came out of the gates strong with many game titles. Some of these game titles included: Farmville, Cityville, Mafia Wars, and Word with Friends. The company priced its Initial public offering price at $10 per share, and at that time was said to be the biggest tech IPO offering since Groupon. 

    It included 100 million shares more »

  • This Biotech Stock Looks Like a Good Investment

    By Terry Chrisomalis - April 6, 2013 | Tickers: IMGN, MRK, SGEN

    The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as ImmunoGen (NASDAQ: IMGN). ImmunoGen uses a system called the "TAP" technology, also known as Targeted Antibody Payload.  

    Currently, antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where ImmunoGen's technology comes into more »

  • This Biotech Stock Might Boost Your Portfolio

    By Terry Chrisomalis - April 4, 2013 | Tickers: BMY, GSK, VICL

    There are many promising biotech companies out there to choose from. One such company, named Vical (NASDAQ: VICL), is targeting a cancer known as Melanoma. Melanoma is the most dangerous form of skin cancer, and is the leading cause of death for skin disease. The company has a good pipeline, but its lead candidate is Allovectin. 

    Allovectin approaching results

    Results from a phase 3 trial are approaching for Allovectin. Allovectin more »

  • Is It The Right Time For Immunogen?

    By Terry Chrisomalis - April 3, 2013 | Tickers: IMGN, MRK, SGEN

    The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as Immunogen (NASDAQ: IMGN). Immunogen uses a system called the "TAP" technology, also known as Targeted Antibody Payload.  Currently antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where Immunogen's technology comes into more »

  • Page 1 of 2